AP2005003200A0 - Piperdine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1. - Google Patents

Piperdine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1.

Info

Publication number: AP2005003200A0
Authority: AP; ARIPO
Prior art keywords: mip; selective inhibitors; receptor ccr1; 1alpha; binding
Prior art date: 2002-07-18

Application number

AP2005003200A

Other languages

English (en)

Inventor

Laura Cook Blumberg

Matthew Frank Brown

Cheryl M Hayward

Christopher Stanley Poss

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-18

Filing date

2003-07-07

Publication date

2005-03-31

2003-07-07 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2005-03-31 Publication of AP2005003200A0 publication Critical patent/AP2005003200A0/xx

Links

102100031172 C-C chemokine receptor type 1 Human genes 0.000 title 1
101710149814 C-C chemokine receptor type 1 Proteins 0.000 title 1
108700012434 CCL3 Proteins 0.000 title 1
102000000013 Chemokine CCL3 Human genes 0.000 title 1
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 1
229940124639 Selective inhibitor Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Virology (AREA)
Psychiatry (AREA)
Oncology (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)

AP2005003200A 2002-07-18 2003-07-07 Piperdine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1. AP2005003200A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US39710802P	2002-07-18	2002-07-18
PCT/IB2003/002876 WO2004009550A1 (fr)	2002-07-18	2003-07-07	Derives de piperidine et leur utilisation comme inhibiteurs selectifs de la liaison mip-1alpha a son recepteur ccr1

Publications (1)

Publication Number	Publication Date
AP2005003200A0 true AP2005003200A0 (en)	2005-03-31

Family

ID=30770997

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2005003200A AP2005003200A0 (en)	2002-07-18	2003-07-07	Piperdine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1.

Country Status (24)

Country	Link
US (1)	US20040063759A1 (fr)
EP (1)	EP1534677A1 (fr)
JP (1)	JP2005537279A (fr)
KR (1)	KR20050021497A (fr)
CN (1)	CN1668592A (fr)
AP (1)	AP2005003200A0 (fr)
AR (1)	AR040583A1 (fr)
AU (1)	AU2003242941A1 (fr)
BR (1)	BR0312946A (fr)
CA (1)	CA2492651A1 (fr)
EC (1)	ECSP055547A (fr)
HN (1)	HN2003000222A (fr)
IL (1)	IL166010A0 (fr)
IS (1)	IS7614A (fr)
MA (1)	MA27326A1 (fr)
MX (1)	MXPA05000380A (fr)
OA (1)	OA12885A (fr)
PA (1)	PA8575901A1 (fr)
PE (1)	PE20040666A1 (fr)
TN (1)	TNSN05014A1 (fr)
TW (1)	TW200402416A (fr)
UY (1)	UY27897A1 (fr)
WO (1)	WO2004009550A1 (fr)
ZA (1)	ZA200500067B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7399790B2 (en)	2001-02-28	2008-07-15	Konowalchuk Thomas W	Virucidal compositions
US7493363B2 (en)	2001-09-19	2009-02-17	Microsoft Corporation	Peer-to-peer group management and method for maintaining peer-to-peer graphs
US7842693B2 (en)	2002-06-12	2010-11-30	Chemocentryx, Inc.	Substituted piperazines
US7589199B2 (en)	2002-06-12	2009-09-15	Chemocentryx, Inc.	Substituted piperazines
EP1531822B1 (fr)	2002-06-12	2009-08-05	ChemoCentryx Inc	Derives de piperazine 1-aryl-4-substitues utilises en tant qu'antagonistes du ccr1 dans le traitement de l'inflammation et des troubles immunitaires
CA2492110A1 (fr) *	2002-07-18	2004-01-29	Pfizer Products Inc.	Derives de piperidine bicycliques utilises comme antagonistes du recepteur de chimiokine ccr1
US8261062B2 (en)	2003-03-27	2012-09-04	Microsoft Corporation	Non-cryptographic addressing
US7479496B2 (en)	2004-02-19	2009-01-20	Bristol-Myers Squibb Company	Substituted spiro azabicyclics as modulators of chemokine receptor activity
US7230022B2 (en)	2004-02-19	2007-06-12	Bristol-Myers Squibb Company	Substituted fused bicyclic amines as modulators of chemokine receptor activity
US7381738B2 (en)	2004-02-19	2008-06-03	Bristol-Myers Squibb Company	Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7288563B2 (en)	2004-02-19	2007-10-30	Bristol-Myers Squibb Company	Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7435830B2 (en)	2004-03-03	2008-10-14	Chemocentryx, Inc.	Bicyclic and bridged nitrogen heterocycles
US7435831B2 (en)	2004-03-03	2008-10-14	Chemocentryx, Inc.	Bicyclic and bridged nitrogen heterocycles
US7929689B2 (en)	2004-06-30	2011-04-19	Microsoft Corporation	Call signs
GT200500375A (es) *	2004-12-20	2006-11-28		Derivados de piperidina y su uso como agentes antiinflamatorios
US7620902B2 (en)	2005-04-20	2009-11-17	Microsoft Corporation	Collaboration spaces
US7617281B2 (en)	2005-04-25	2009-11-10	Microsoft Corporation	System and method for collaboration with serverless presence
US7660851B2 (en)	2005-07-06	2010-02-09	Microsoft Corporation	Meetings near me
SI1907374T1 (sl)	2005-07-26	2012-11-30	Glaxo Group Ltd	Derivati benzilpiperazina uporabni za zdravljenje gastrointestinalnih motenj
WO2007073432A2 (fr)	2005-10-11	2007-06-28	Chemocentryx, Inc.	Derives de la piperidine et procedes d’utilisation
US8086842B2 (en)	2006-04-21	2011-12-27	Microsoft Corporation	Peer-to-peer contact exchange
US8069208B2 (en)	2006-04-21	2011-11-29	Microsoft Corporation	Peer-to-peer buddy request and response
WO2009051244A1 (fr) *	2007-10-18	2009-04-23	Takeda Pharmaceutical Company Limited	Composé hétérocyclique
WO2010077915A1 (fr) *	2008-12-17	2010-07-08	Forest Laboratories Holdings Limited	Nouveaux composés utiles comme ligands de récepteur de chémokine cc
WO2015091645A1 (fr)	2013-12-18	2015-06-25	Basf Se	Composés d'azole transportant un substituant dérivé d'imine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE640616A (fr) *	1962-12-19
US3492397A (en) *	1967-04-07	1970-01-27	Warner Lambert Pharmaceutical	Sustained release dosage in the pellet form and process thereof
US4060598A (en) *	1967-06-28	1977-11-29	Boehringer Mannheim G.M.B.H.	Tablets coated with aqueous resin dispersions
US3538214A (en) *	1969-04-22	1970-11-03	Merck & Co Inc	Controlled release medicinal tablets
US4173626A (en) *	1978-12-11	1979-11-06	Merck & Co., Inc.	Sustained release indomethacin
WO1997024325A1 (fr) *	1995-12-28	1997-07-10	Takeda Chemical Industries, Ltd.	DERIVES DE DIPHENYLMETHANE UTILISES COMME ANTAGONISTES DU RECEPTEUR MIP-1α/RANTES
CA2373942A1 (fr) *	1999-05-18	2000-11-23	Teijin Limited	Remedes ou prophylactase contre les maladies associees a des chimiokines
AR028947A1 (es) *	2000-06-20	2003-05-28	Astrazeneca Ab	Compuestos novedosos
CA2453383C (fr) *	2001-07-24	2010-04-06	Richter Gedeon Vegyeszeti Gyar Rt	Derives de piperidine utilises en tant qu'antagonistes du recepteur n-methyl-d-aspartate (nmda)

2003
- 2003-06-17 PA PA20038575901A patent/PA8575901A1/es unknown
- 2003-07-07 AP AP2005003200A patent/AP2005003200A0/xx unknown
- 2003-07-07 CA CA002492651A patent/CA2492651A1/fr not_active Abandoned
- 2003-07-07 AU AU2003242941A patent/AU2003242941A1/en not_active Abandoned
- 2003-07-07 MX MXPA05000380A patent/MXPA05000380A/es unknown
- 2003-07-07 JP JP2004522601A patent/JP2005537279A/ja active Pending
- 2003-07-07 OA OA1200500010A patent/OA12885A/en unknown
- 2003-07-07 WO PCT/IB2003/002876 patent/WO2004009550A1/fr not_active Ceased
- 2003-07-07 CN CNA038170922A patent/CN1668592A/zh active Pending
- 2003-07-07 EP EP03765230A patent/EP1534677A1/fr not_active Withdrawn
- 2003-07-07 BR BR0312946-2A patent/BR0312946A/pt not_active Application Discontinuation
- 2003-07-07 KR KR10-2005-7000849A patent/KR20050021497A/ko not_active Withdrawn
- 2003-07-08 US US10/616,844 patent/US20040063759A1/en not_active Abandoned
- 2003-07-15 PE PE2003000705A patent/PE20040666A1/es not_active Application Discontinuation
- 2003-07-16 AR AR20030102555A patent/AR040583A1/es unknown
- 2003-07-16 UY UY27897A patent/UY27897A1/es not_active Application Discontinuation
- 2003-07-17 HN HN2003000222A patent/HN2003000222A/es unknown
- 2003-07-17 TW TW092119550A patent/TW200402416A/zh unknown
2004
- 2004-12-23 IS IS7614A patent/IS7614A/is unknown
- 2004-12-27 IL IL16601004A patent/IL166010A0/xx unknown
2005
- 2005-01-04 ZA ZA200500067A patent/ZA200500067B/en unknown
- 2005-01-18 EC EC2005005547A patent/ECSP055547A/es unknown
- 2005-01-18 MA MA28049A patent/MA27326A1/fr unknown
- 2005-01-18 TN TNP2005000014A patent/TNSN05014A1/fr unknown

Also Published As

Publication number	Publication date
CA2492651A1 (fr)	2004-01-29
PA8575901A1 (es)	2004-07-20
KR20050021497A (ko)	2005-03-07
MA27326A1 (fr)	2005-05-02
US20040063759A1 (en)	2004-04-01
MXPA05000380A (es)	2005-03-31
HN2003000222A (es)	2004-11-23
OA12885A (en)	2006-09-15
JP2005537279A (ja)	2005-12-08
ZA200500067B (en)	2005-11-02
TNSN05014A1 (fr)	2007-05-14
ECSP055547A (es)	2005-03-10
EP1534677A1 (fr)	2005-06-01
IS7614A (is)	2004-12-23
IL166010A0 (en)	2006-01-15
AU2003242941A1 (en)	2004-02-09
UY27897A1 (es)	2004-02-27
TW200402416A (en)	2004-02-16
PE20040666A1 (es)	2004-09-25
CN1668592A (zh)	2005-09-14
WO2004009550A1 (fr)	2004-01-29
BR0312946A (pt)	2005-07-12
AR040583A1 (es)	2005-04-13

Publication	Publication Date	Title
AP2005003200A0 (en)	2005-03-31	Piperdine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1.
ZA200500680B (en)	2006-08-30	Quinoline derivatives and their use as mycrobacterial inhibitors
IL173398A0 (en)	2006-06-11	Pyridyl derivatives and their use as therapeutic agents
IL180872A0 (en)	2007-07-04	Substituted 8-aminoalkylthio-xanthines, and the use thereof as inhibitors of the dipeptidyl peptidase iv
IL178339A0 (en)	2007-02-11	Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
EP1843768A4 (fr)	2009-10-21	Morphinanes substitues et leurs procedes d'utilisation
IL182527A0 (en)	2007-09-20	Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
AU2003232848A8 (en)	2003-12-31	Phenylaminopyrimidines and their use as rho-kinase inhibitors
EP1729761A4 (fr)	2008-09-03	Traitement de cadasil avec des inhibiteurs de la cholinesterase
EP1727542A4 (fr)	2009-08-05	Composes, compositions, procedes de fabrication, et procedes d'utilisation destines inhiber le facteur d'inhibition de la migration des macrophages
EP1703907A4 (fr)	2009-03-25	Compositions et procedes permettant de traiter des etats pathologiques recurrents
AU2003215756A8 (en)	2003-10-08	Benzimidazoles and their use as mitogen-activated- and rho-kinase inhibitors
IL174497A0 (en)	2006-08-01	Pyridine derivatives and use thereof as urotensin ii antagonists
PL1751175T3 (pl)	2013-03-29	Antagoniści receptora IL-1, kompozycje i sposoby leczenia
IL175179A0 (en)	2006-09-05	Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
ZA200606070B (en)	2007-12-27	Substituted quinolines and their use as mycrobacterial inhibitors
IL176772A0 (en)	2006-10-31	Acylaminothiazole derivatives and use thereof as beta-amyloid inhibitors
PL380189A3 (pl)	2007-01-08	Azolidynokarbonitryle i ich zastosowanie jako inhibitory DPP-IV
EP1670314A4 (fr)	2009-02-25	Procedes et compositions renfermant des diamines comme nouveaux produits therapeutiques antituberculeux
EP1601348A4 (fr)	2008-12-10	Compositions et methodes presentant une activite therapeutique amelioree
EP1750697A4 (fr)	2009-08-26	Procédés et compositions utilisant des médicaments d'inhibition de la cytokine pour le traitement et la gestion de cancers et d'autres maladies
IL180195A0 (en)	2007-06-03	Aequorin-containing compositions and methods of using same
GB0611789D0 (en)	2006-07-26	Methods and compositions relating to ccr5 antagonist,ifn-&gammed;and il-13 induced inflammation
AU2003263988A8 (en)	2004-02-23	Methods and compositions to treat conditions associated with neovascularization
ZA200607436B (en)	2009-04-29	Chemokine inhibiting piperazine derivatives and their use to treat multiple myeloma